G. Witt

发表

Pharmacokinetics and Pharmacodynamics of Zileuton after Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy Volunteers

L. Dubé, G. Granneman, W. Awni, 1995, Clinical pharmacokinetics.

Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5‐lipoxygenase inhibitor (ABT‐761) in healthy volunteers

R. Hansen, Shekman L. Wong, W. Awni, 1998, Clinical pharmacology and therapeutics.

The Effect of Food on the Pharmacokinetics of Zileuton

L. Dubé, G. Granneman, J. Cavanaugh, 1995, Clinical pharmacokinetics.

Pharmacokinetic Interactions between Zileuton and Prednisone

L. Dubé, G. Granneman, J. Cavanaugh, 1995, Clinical pharmacokinetics.

Age-Dependent Pharmacokinetics of Lansoprazole in Neonates and Infants

M. Kukulka, Weijiang Zhang, G. Witt, 2008, Paediatric drugs.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

J. Leonard, A. Molla, N. Lyons, 1997, Antimicrobial agents and chemotherapy.

Lack of a Clinically Significant Pharmacokinetic Drug Interaction Between Tiagabine and Valproate

G. Granneman, K. Sommerville, L. Gustavson, 1998, American journal of therapeutics.

Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam

E. Samara, J. Cavanaugh, G. Witt, 1997, Journal of clinical pharmacology.

Multiple-Dose Evaluation of the Absorption Characteristics of Divalproex Sodium Tablets, a Delayed-Release Preparation of Valproate, in Healthy Volunteers

J. Cavanaugh, J. Lamm, A. H. Chun, 1995 .

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.

G. Granneman, J. Cavanaugh, D. Schneck, 1996, The Journal of clinical psychiatry.

S1095 The Pharmacokinetics of TAK-390mr 60 mg, a Dual Delayed Release Formulation of the Proton Pump Inhibitor TAK-390, and Lansoprazole 60 mg: A Retrospective Analysis

D. Mulford, M. Vakily, G. Witt, 2008 .